Moreover, in curatively treated patients with stage III–IV disease, SATB2 expression was a predictor of response to adjuvant chemotherapy, irrespective of tumour location, and in patients with rectal cancer, a significant interaction between high SATB2 expression and response to neoadjuvant therapy was observed. Here, SATB2 is linked to neoplasm.